Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone 12 mg vs 6 mg for Thromboembolic Events in Critical COVID-19
NCT05195242Phase 3Completed
- Sponsor
- Karolinska Institutet
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexamethasone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Number of patients discharged alive from the ICU without thromboembolic events. Started Aug 2020; status: completed.
02
Drugs
dexamethasone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05195242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195242.